News

BioPharma Dive2h
Sarepta woes mount as Duchenne gene therapy knocked back in Europe
The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...
Layoffs, shutdowns and billions up in smoke. What's wrong with Bay Area biotech?
Since late 2022, bad news in biotech has been nearly inescapable: flopped trials, slashed drug pipelines, bankruptcies and ...
100 days into the job, FDA head talks to CNN about agency goals— and Coke’s switch to sugar
Commissioner Marty Makary says the FDA will plow ahead with big plans on ultra process foods, dietary guidelines and ...
Richmond Times-Dispatch1d
Virginia's HIV/AIDS patients to lose services because of federal cuts
A sharp drop in funds from the federal program to help people with HIV/AIDS means the state is dropping key services for ...
Science-Based Medicine1dOpinion
FDA Has Replaced its Leadership With Doctors Who Have Done Their “Research”
A large tertiary care center in Sydney, Australia is pulling out all the stops to try and cut their expenses. As of next ...
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares ...
Dermatology Advisor2d
Thousands Laid off From NIH, FDA and CDC After Supreme Court Decision
Last Monday, the U.S. Department of Health and Human Services (HHS) finalized 10,000 layoffs across federal health agencies, including the National Institutes of Health (NIH), U.S. Food and Drug ...
STAT2d
FDA’s new top drug regulator hails from industry
This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...
Government’s H.R. Arm Shedding a Third of Staff
More than 750 workers have resigned with incentives, and more than 150 others have resigned without. The agency has also laid ...
STAT3d
New head of FDA drug center is a biotech veteran and an outspoken critic of the academic establishment
“Dr. Tidmarsh is an accomplished physician-scientist and leader whose experience spans the full arc of drug development — ...
FDA appoints biotech executive as top drug regulator under RFK Jr.
Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the agency’s ...
KFF Health News4d
NIH, FDA Cuts Would Lead To Fewer New Meds, CBO Analysis Indicates
An estimated 53 drugs would not enter the market in the next 30 years if the NIH is hit with a permanent 10% budget cut and the FDA experiences a nine-month drug review delay due to staffing cuts, the ...